Objectif
The rise of antimicrobial resistance (AMR) is a major threat to global public health as it will cause 10 million deaths per year by 2050. The rise in AMR is largely driven by the abundant mis- and overuse of antimicrobial drugs in humans and animals. As such, there is a strong demand to reduce the use of antimicrobials in animals, putting cattle farmers under enormous pressure to change their current way of working. However, the lack of appropriate alternatives is hindering them to renounce from (over)using antimicrobials as their production output and income are at risk.
At FarmPharma, we are on the mission to provide effective, safe and affordable solutions to keep livestock animals healthy and well. To do so, we are developing InterferOx, an interferon-based, immune-stimulating, anti-infective therapy for cattle with the unique ability to treat AND prevent viral AND bacterial infections. InterferOx can thus minimize the use of antimicrobials in cattle by providing farmers an effective and sustainable alternative, thereby providing a solution for the rise in AMR.
The global market volume is 1.5 billion cattle, with our total addressable markets of Europe and US accounting for 121 and 94 million, respectively. With InterferOx, we respond to the trends and needs of our €1.7 billion target market: the cattle antimicrobials market. We aim to commercialize InterferOx via a licensing deal with a pharmaceutical company after completing clinical validation. In return, we will receive upfront, milestone and royalty payments with an estimated value of €77.8 million within the next 7 years.
To maximize our chance of realizing this promising future, we will perform a feasibility study, focusing on market analysis, commercialization strategy, IP strategy and value chain, to deliver a consolidated business plan. This will give us a clear understanding of the commercial potential of InterferOx, strengthen our current infrastructure, and define our optimal business strategy.
Champ scientifique
CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN.
CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- agricultural sciencesanimal and dairy sciencedomestic animalsanimal husbandry
- medical and health scienceshealth sciencespublic healthepidemiologyzoonosis
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
754 50 UPPSALA
Suède
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.